PetMed Express (PETS) 27th Annual ICR Conference 2025 summary
Event summary combining transcript, slides, and related documents.
27th Annual ICR Conference 2025 summary
10 Jan, 2026Business transformation and strategy
Focused on modernizing and accelerating the business, leveraging its legacy as the first online pet pharmacy with nearly 30 years of experience.
Emphasized the pharmacy as the core strength, with licenses in all 50 states and a robust verification process for prescriptions.
Expanded product offerings beyond pharmaceuticals to include food, over-the-counter products, and science-backed, veterinarian-approved items.
Rebranded to position as a consumer pet healthcare company, not just a retailer, with a focus on health, wellness, and pet longevity.
Reduced SKUs from over 16,000 to about 11,000 to focus on high-margin, purpose-aligned products.
Operational and technology initiatives
Achieved $5 million in annualized cost savings through operational efficiencies and expense reduction.
Launched a new website, mobile app, and buy now pay later platform, and upgraded the tech stack including order management and Autoship systems.
Implemented new customer service technologies, including automation and self-service tools, and upgraded call center systems.
Focused on optimizing recent tech investments before making further foundational changes.
Marketing, branding, and customer acquisition
Undertook a major rebranding and repositioning effort to attract younger, higher-income customers, especially Millennials and Gen Z.
Expanded marketing channels to include radio, CTV, billboards, and podcasts, with a focus on creative messaging and targeted outreach.
Delayed significant marketing spend until foundational digital and branding work was complete; now ramping up targeted campaigns.
Latest events from PetMed Express
- Sales dropped 22.7% and a $26.7M goodwill impairment led to a $34.2M net loss.PETS
Q1 202617 Feb 2026 - Sales and margins fell sharply, with a $53M net loss and major impairments amid ongoing headwinds.PETS
Q3 202617 Feb 2026 - Net sales fell 13% but net income rose to $3.8M, aided by a one-time stock comp reversal.PETS
Q1 20252 Feb 2026 - Q4 sales up 6.6% to $66.5M, but losses widened; focus on tech, efficiency, and growth.PETS
Q4 20241 Feb 2026 - Digital transformation, product expansion, and operational efficiency drive future growth.PETS
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Net sales dropped 16.1% to $59.6M, but margin and net income rose; dividend suspended.PETS
Q2 202516 Jan 2026 - Sales fell 23.6% and a $26.7M goodwill impairment led to a net loss for the quarter.PETS
Q2 202619 Dec 2025 - Sales dropped 18.9% but gross margin and adjusted EBITDA improved on cost controls.PETS
Q3 202517 Dec 2025 - Shareholders will vote on director elections, executive pay, auditor ratification, and enhanced ESG governance.PETS
Proxy Filing10 Dec 2025